NY

MarketAxess to Host Conference Call Announcing Second Quarter 2020 Results on Wednesday, July 22, 2020

MarketAxess, Financial markets, Market liquidity, Finance
Tuesday, July 7, 2020 - 11:00am

To access the conference call, please dial 855-425-4206 (U.S.) or 484-756-4249 (international).

Key Points: 
  • To access the conference call, please dial 855-425-4206 (U.S.) or 484-756-4249 (international).
  • The Company will also host a live audio Webcast of the conference call on the Investor Relations section of the Company's website at http://investor.marketaxess.com .
  • MarketAxess operates a leading, institutional electronic trading platform delivering expanded liquidity opportunities, improved execution quality and significant cost savings across global fixed-income markets.
  • Drawing on its deep data and analytical resources, MarketAxess provides automated trading solutions, market data products and a range of pre- and post-trade services.

FXCM Reduces Min Trade Size on Single Stock CFDs - Now Zero Commission and Fractional Shares Available

Foreign exchange companies, FXCM, Finance, Financial economics, Investment
Tuesday, July 7, 2020 - 9:00am

Share price and margin requirements update and should be viewed on FXCM trading platforms.

Key Points: 
  • Share price and margin requirements update and should be viewed on FXCM trading platforms.
  • With fractional trading available, this is exactly what we are providing; a user-friendly service allowing anyone to trade companies in a way that allows them flexible trade sizes.
  • Combined with our commission-free single stock CFD pricing structure, we have made the trading of household named shares more accessible than ever before.
  • Read and understand the Terms and Conditions on the FXCM Groups websites prior to taking further action.

Pomerantz Law Firm Announces the Filing of a Class Action against Co-Diagnostics, Inc. and Certain Officers – CODX

Abraham Pomerantz, Pomerantz
Tuesday, July 7, 2020 - 12:08am

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (Co-Diagnostics or the Company)(NASDAQ: CODX) and certain of its officers.

Key Points: 
  • NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (Co-Diagnostics or the Company)(NASDAQ: CODX) and certain of its officers.
  • In the late morning and early afternoon of May 14, 2020, third parties revealed startling information about Co-Diagnostics allegedly 100% accurate test.
  • The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

ROSEN, A TOP RANKED LAW FIRM, Continues Its Investigation of Securities Claims Against J2 Global, Inc. – JCOM

Stock market, Securities Class Action, Security
Tuesday, July 7, 2020 - 12:03am

On June 30, 2020, Hindenburg Research issued a report that detailed a series of alarming red flags about J2.

Key Points: 
  • On June 30, 2020, Hindenburg Research issued a report that detailed a series of alarming red flags about J2.
  • The report alleged that J2 is a digital media roll-up that has acquired 186 businesses since its inception.
  • If you purchased securities of J2 please visit the firms website at http://www.rosenlegal.com/cases-register-1893.html to join the securities action.
  • Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline – ENDP

Abraham Pomerantz, Pomerantz, Endo, Companies
Tuesday, July 7, 2020 - 12:00am

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Endo International plc (Endo or the Company) (NASDAQ: ENDP) and certain of its officers.

Key Points: 
  • NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Endo International plc (Endo or the Company) (NASDAQ: ENDP) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sorrento Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – SRNE

Life sciences, Articles, Biotechnology, Abraham Pomerantz, Pomerantz, Autoimmunity, Biopharmaceutical
Monday, July 6, 2020 - 11:48pm

To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Sorrento is a clinical-stage biopharmaceutical company that engages in the development of therapies for the treatment of cancer, autoimmune, inflammatory, and neurodegenerative diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Wells Fargo & Company of Class Action Lawsuit and Upcoming Deadline – WFC

Abraham Pomerantz, Wells Fargo, Fargo, Pomerantz, WFC, Securities Class Action, Companies, Financial services, Finance
Monday, July 6, 2020 - 11:41pm

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Wells Fargo & Company (Wells Fargo or the Company) (NYSE: WFC) and certain of its officers.

Key Points: 
  • NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Wells Fargo & Company (Wells Fargo or the Company) (NYSE: WFC) and certain of its officers.
  • If you are a shareholder who purchased Wells Fargo securities during the class period, you have until August 3, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.
  • To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hebron Technology Co. - HEBT

Abraham Pomerantz, Pomerantz, Hebron, Historical geography, Jewish history, Human geography
Monday, July 6, 2020 - 11:35pm

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Hebron Technology Co. (Hebron or the Company) (NASDAQ: HEBT).

Key Points: 
  • NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Hebron Technology Co. (Hebron or the Company) (NASDAQ: HEBT).
  • Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
  • On June 3, 2020, the investment analyst firm Grizzly Research published a report, entitled We Believe Hebron Technology Co., Ltd. (HEBT) is an Insider Enrichment Scheme without Economic Basis.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of Directors

Cellectis, Board of directors, Arthaud, Business, Companies, Articles
Monday, July 6, 2020 - 10:19pm

Calyxts Board of Directors has appointed Yves Ribeill, Ph.D., currently a Calyxt Board member, as Chairman, effective immediately.

Key Points: 
  • Calyxts Board of Directors has appointed Yves Ribeill, Ph.D., currently a Calyxt Board member, as Chairman, effective immediately.
  • Additionally, Calyxts Board of Directors appointed Laurent Arthaud, Cellectis Board member, as a Cellectis designated Director, effective immediately.
  • In addition, the Calyxt Board of Directors appointed Laurent Arthaud, a member of Cellectis Board of Directors since 2011, as Director.
  • Mr. Arthaud served as a member of Calyxts Board of Directors until May 2019 and is a member of Cellectis Board of Directors since 2011.

Cellectis Reports Clinical Hold Placed on MELANI-01 Study

Health, Drug discovery, Cellectis, Clinical trial, Multiple myeloma
Monday, July 6, 2020 - 9:33pm

This clinical hold which impacts one of the three Cellectis product candidates currently in clinical studies, was initiated following the submission of a safety report regarding one patient enrolled in the MELANI-01 study at dose level two (DL2), with relapsed and refractory multiple myeloma.

Key Points: 
  • This clinical hold which impacts one of the three Cellectis product candidates currently in clinical studies, was initiated following the submission of a safety report regarding one patient enrolled in the MELANI-01 study at dose level two (DL2), with relapsed and refractory multiple myeloma.
  • We share the FDAs commitment to patient safety and are working collaboratively with the agency and the investigators to resolve this clinical hold, said Carrie Brownstein, MD, Chief Medical Officer, Cellectis.
  • MELANI-01 is a Phase 1 open-label First-In-Human dose escalation clinical study evaluating UCARTCS1A product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM).
  • These forward-looking statements include statements regarding Cellectis responses to the FDA requests, the timing of clinical protocol amendments and the resolution of the FDA clinical hold.